Manja Ahola
Orion Corporation
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Manja Ahola.
Biomaterials | 2000
Pirjo Kortesuo; Manja Ahola; Ilkka Kangasniemi; Antti Yli-Urpo; Juha Kiesvaara
The purpose of the present study was to examine controlled delivery of toremifene citrate from subcutaneously implanted silica xerogel carrier and to evaluate silica xerogel related tissue effects after implantation. Toremifene citrate was incorporated into hydrolyzed silica sol in a room temperature process. Toremifene citrate treated silica xerogel implants were tested both in vitro and in vivo using healthy mice. Silica xerogel with tritium-labelled toremifene was implanted subcutaneously in mice for 42 d. To determine the amount of tritiated toremifene remaining in the silica discs at the implantation site, the discs were excised periodically and radioactivity measured. The amount of tritiated toremifene in the implant after 42 d was still about 16% and the amount of silica xerogel about 25%. In a histopathological study silica xerogel did not show any tissue irritation at the site of the implantation. A fibrotic capsule was formed around the implant. No silica xerogel related histological changes in liver, kidney, lymph nodes and uterus were observed during the implantation period. The silica xerogel discs showed a sustained release of toremifene citrate over 42 d. Histologically, toremifene-related changes in the uterus were also detectable at all studied time points. These findings suggest that silica xerogel is a promising carrier material for implantable controlled drug delivery system.
Journal of Non-crystalline Solids | 2002
Teresa Czuryszkiewicz; Jarno Ahvenlammi; Pirjo Kortesuo; Manja Ahola; Freddy Kleitz; Mika Jokinen; Mika Lindén; J.B. Rosenholm
Abstract Sol–gel derived biodegradable SiO 2 gel fibers have been prepared and characterized by Raman spectroscopy, SEM, 29 Si MAS NMR and TG–MS, respectively. An active component, dexmedetomidine hydrochloride, was incorporated in situ into the fiber structure, by adding it to the sol used for fiber spinning. The subsequent release of the active component was studied in vitro and shown to be determined by differences in the fiber structure, for which clear but indirect evidence was obtained from the different characterization methods used.
Archive | 2000
Manja Ahola; Risto Penttinen; Anders Södergård; Antti Yli-Urpo
Archive | 2002
Manja Ahola; Heidi Fagerholm; Ilkka Kangasniemi; Juha Kiesvaara; Pirjo Kortesuo; Kauko Oiva Antero Kurkela; Niilo Saarinen; Antti Yli-Urpo
Archive | 2000
Manja Ahola; Eija Säilynoja; Jukka Salonen; Risto Penttinen; Antti Yli-Urpo
Archive | 2000
Mika Jokinen; Timo Peltola; Sinikka Veittola; Manja Ahola; Pirjo Kortesuo
Archive | 2002
Mika Koskinen; Eija Säilynoja; Manja Ahola; Harry Jalonen; Jukka Salonen; Veli-Matti Kähäri
Archive | 2018
Joonas Mikkonen; Taina Tjäder; Mikael Stolt; Manja Ahola
Archive | 2017
Harri Jukarainen; Heikki Lyytikäinen; Manja Ahola; Mikael Stolt; Pirjo Kortesuo; Stefan Bracht
Archive | 2013
Stefan Bracht; Pirjo Kortesuo; Mikael Stolt; Manja Ahola; Harri Jukarainen; Heikki Lyytikinen